politics
Eli Lilly Reports Weight Loss Improvement in Mid-Stage Obesity Trial
30 Eylül 2026CNBC
- Eli Lilly announced positive results for its obesity treatment combining eloralintide and tirzepatide, with Phase 3 trials planned.
- Eli Lilly has announced promising results from a mid-stage trial of a combination obesity treatment that includes its amylin drug eloralintide and tirzepatide. The company plans to initiate Phase 3 trials for this regimen by the end of the year.
- This development is seen as a significant step forward in the fight against obesity, which has become a major public health concern.
- Obesity is a growing epidemic worldwide, with significant health implications including diabetes, heart disease, and other chronic conditions. Eli Lilly's ongoing research and development in this area reflect the increasing focus on innovative treatments that address this complex issue.
- The combination of eloralintide and tirzepatide could represent a breakthrough in obesity treatment, potentially offering a more effective solution than existing therapies. As obesity rates continue to rise globally, the success of this regimen in Phase 3 trials will be closely monitored by both investors and health…
NewsAI özeti
This article is for informational purposes only and does not constitute medical advice. Please consult a healthcare professional for medical concerns.
Orijinal Kaynak
Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.
Kaynağı Görüntüleİlgili Haberler
Tümünü Gör
NewsAI Mobil Uygulamaları
Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.